# 2025年12月8日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 职业体力活动与40.4万名成年人中14种癌症的发病率和死亡率的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353444)
**期刊：** Nature communications
**PMID：** 41353444
**DOI：** 10.1038/s41467-025-65326-6

### 第一部分 原文与翻译

**英文原标题：** Occupational physical activity and incidence and mortality of 14 cancers in 404,249 adults.

> **英文摘要：**
> Leisure physical activity is considered protective against several cancers, but the impact of physical activity at work remains unclear. We analyze data from over 400,000 Norwegian adults followed for a median of 27 years to examine how different levels of occupational physical activity are associated with cancer incidence and mortality. Participants report their typical work activity as sedentary, walking, walking-and-lifting, or heavy labor. Here we show that individuals with more physically active jobs have a lower risk of developing several cancers (i.e., endometrial, colon, breast, rectal, and prostate), and to a lesser extent, the risk of breast cancer mortality. However, occupational physical activity is also associated with increased risk of esophageal and kidney cancer death. These findings suggest that occupational physical activity may lower the incidence of some cancers but are associated with a higher mortality from other cancer types. Understanding these patterns could help tailor public health recommendations related to physical activity and occupational health.

> **中文摘要：**
> 休闲体力活动被认为对多种癌症具有保护作用，但工作中的体力活动对癌症的影响仍不清楚。我们分析了超过40万名挪威成年人的数据，这些受试者的中位随访时间为27年，以探讨不同水平的职业体力活动与癌症发病率及死亡率之间的关系。参与者报告其典型的工作活动类型，包括久坐、步行、步行并搬运或重体力劳动。研究结果显示，从事体力活动较多职业的人群发生多种癌症（如子宫内膜癌、结肠癌、乳腺癌、直肠癌和前列腺癌）的风险较低，且乳腺癌死亡风险也呈轻微降低。然而，职业体力活动同时与食管癌和肾癌死亡风险的增加有关。这些发现表明，职业体力活动可能降低某些癌症的发病率，但也可能与其他癌症类型的更高死亡率相关。理解这些模式有助于制定更有针对性的与体力活动和职业健康相关的公共卫生建议。

### 第二部分 AI 大师评价

该研究利用大规模、长期随访的挪威人群数据，系统评估了职业体力活动水平与14种癌症的发病及死亡风险之间的关系。结果揭示，较高的职业体力活动与某些癌症的较低发病风险相关，但也伴随其他癌症类型死亡风险的升高。这一研究在职业健康与癌症流行病学交叉领域提供了新的量化证据，强调了不同类型体力活动可能具有差异性的健康效应。其创新在于区分工作性与休闲性体力活动的长期健康影响，但局限性包括职业活动评估依赖自我报告，可能存在分类偏倚。

---

## 2. 既有抗复制酶免疫对自我扩增型 mRNA 疫苗效力的影响

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353442)
**期刊：** Nature communications
**PMID：** 41353442
**DOI：** 10.1038/s41467-025-66993-1

### 第一部分 原文与翻译

**英文原标题：** Impact of pre-existing anti-replicase immunity on the efficacy of self-amplifying mRNA vaccines.

> **英文摘要：**
> Self-amplifying mRNA vaccines use a viral replicase for self-amplification. It is currently unclear whether anti-replicase immunity occurs after saRNA vaccination, and whether such pre-existing anti-replicase immunity impacts the efficacy of subsequent saRNA vaccines. Using female mice, this study demonstrates that an initial saRNA vaccination schedule elicits replicase-specific immunity, which reduces the in vivo expression and impairs the Th1 cell responses of subsequent saRNA vaccines. Passive transfer experiments demonstrate that the suppression of T cell responses is driven by a synergistic effect of both anti-replicase antibodies and anti-replicase T cells. Interestingly, pre-existing anti-replicase immunity does not affect the ability of an influenza saRNA vaccine to provide full protection against an H5N1 challenge in female mice. Taken together, these results provide crucial insights on the effects of anti-replicase immunity induced by a first saRNA vaccination schedule on the expression, immunogenicity and protection efficacy of a subsequent saRNA vaccine.

> **中文摘要：**
> 自我扩增型 mRNA 疫苗利用病毒复制酶实现自我扩增。目前尚不清楚接种自我扩增 RNA（saRNA）疫苗后是否会产生抗复制酶免疫，以及这种既有的抗复制酶免疫是否会影响后续 saRNA 疫苗的效力。本研究以雌性小鼠为模型，证明首次的 saRNA 疫苗接种可诱导针对复制酶的特异性免疫，从而降低后续 saRNA 疫苗的体内表达水平，并削弱其 Th1 细胞反应。被动转移实验表明，T 细胞应答的抑制由抗复制酶抗体和抗复制酶 T 细胞的协同作用所驱动。有趣的是，既有抗复制酶免疫并不影响流感 saRNA 疫苗在雌性小鼠中对 H5N1 挑战所提供的完全保护能力。综上所述，这些结果为理解初次 saRNA 疫苗接种所诱导的抗复制酶免疫对后续 saRNA 疫苗的表达、免疫原性及保护效力的影响提供了重要见解。

### 第二部分 AI 大师评价

该研究旨在探讨自我扩增型 mRNA 疫苗接种后产生的抗复制酶免疫如何影响后续疫苗的效力。通过在雌性小鼠中进行免疫实验和被动转移研究，作者发现抗复制酶抗体与 T 细胞可协同抑制后续疫苗的 Th1 反应和体内表达。值得注意的是，这种免疫并不影响针对 H5N1 的保护效应。研究揭示了 saRNA 疫苗设计中“自我成分免疫干扰”的潜在机制，对优化多次接种策略具有重要启示，但其物种特异性和长期影响仍需进一步验证。

---

## 3. 通过 SHH 和 PTCH1 通路，抑制 CSNK1D 可抑制头颈鳞状细胞癌的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353440)
**期刊：** Cell death & disease
**PMID：** 41353440
**DOI：** 10.1038/s41419-025-08276-7

### 第一部分 原文与翻译

**英文原标题：** CSNK1D inhibition suppresses head and neck squamous cell carcinoma progression through SHH and PTCH1 pathway.

> **英文摘要：**
> Casein kinase 1δ (CK1δ, encoded by casein kinase 1 delta) (CSNK1D) is a serine/threonine protein kinase closely associated with cancer development. However, the biological functions of CSNK1D in head and neck squamous cell carcinoma (HNSCC) remain unclear. This study identifies CSNK1D as a previously unrecognized yet crucial regulator in the progression of HNSCC. CSNK1D expression levels were upregulated in tumor tissues and the up-regulation was positively correlated with poor survival in patients with HNSCC. Moreover, CSNK1D selectively bound SHH and PTCH1, and regulated the stability of the CSNK1D-SHH-PTCH1 complex to control the GLI1-BCL2 axis, leading to the downstream activation of the hedgehog pathway. SB-203580 could target and inhibit CSNK1D, offering new perspectives for the clinical treatment of HNSCC. Overall, CSNK1D is underscored as a vital oncogenic driver and promising therapeutic target for HNSCC.

> **中文摘要：**
> 酪蛋白激酶 1δ（CK1δ，由酪蛋白激酶 1 δ 基因 CSNK1D 编码）是一种与癌症发生密切相关的丝氨酸/苏氨酸蛋白激酶。然而，CSNK1D 在头颈鳞状细胞癌（HNSCC）中的生物学功能仍不清楚。本研究将 CSNK1D 鉴定为 HNSCC 进展过程中一个此前未被认识但至关重要的调控因子。肿瘤组织中 CSNK1D 表达水平上调，且其上调与 HNSCC 患者的不良生存预后呈正相关。此外，CSNK1D 可选择性结合 SHH 和 PTCH1，并调节 CSNK1D-SHH-PTCH1 复合物的稳定性，以控制 GLI1-BCL2 轴，从而激活下游的 Hedgehog 信号通路。SB-203580 可靶向并抑制 CSNK1D，为 HNSCC 的临床治疗提供了新的思路。总体而言，CSNK1D 被强调为 HNSCC 中重要的致癌驱动因子和潜在的治疗靶点。

### 第二部分 AI 大师评价

该研究聚焦于 CSNK1D 在头颈鳞状细胞癌中的作用，揭示其通过 SHH-PTCH1 信号通路促进肿瘤进展的机制。研究利用表达分析和功能验证证实 CSNK1D 的上调与患者预后不良相关，并揭示其调控 GLI1-BCL2 轴以激活 Hedgehog 通路。发现 SB-203580 能抑制 CSNK1D，为靶向治疗提供潜在方向。该工作在机制解析和药物干预层面具有创新性，但仍需进一步临床验证其安全性与疗效。

---

## 4. 脂质连接糖转移的机制快照

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353435)
**期刊：** Nature communications
**PMID：** 41353435
**DOI：** 10.1038/s41467-025-66769-7

### 第一部分 原文与翻译

**英文原标题：** Mechanistic snapshots of lipid-linked sugar transfer.

> **英文摘要：**
> Enzymes undergo dynamic conformational changes during catalysis, yet conventional high-resolution structural methods typically capture only the most stable states. Here, we address this gap using rapid UV photolysis of a chemically caged substrate with cryogenic time-resolved electron microscopy (cryo-TREM). We elucidate the catalytic mechanism of GtrB, a membrane-bound glycosyltransferase that transfers glucose from UDP-glucose to the lipid carrier undecaprenyl phosphate. We visualized how GtrB, which has an active site ~15 Å from the membrane, transitions during the catalytic cycle to move each substrate in proximity for catalysis. From a single dataset, we resolved distinct conformational states: the initial substrate-bound state, a catalytically poised intermediate, and the product-bound state. Through molecular dynamics simulations and biochemical analyses, we identify coordinated movements within the active site that drive catalysis. These findings provide a molecular framework for understanding how glycosyltransferases function and highlight a broadly applicable strategy for capturing dynamic enzymatic states in native-like environments.

> **中文摘要：**
> 酶在催化过程中会经历动态的构象变化，但传统的高分辨率结构分析方法通常只能捕获最稳定的状态。在本研究中，我们利用对化学封闭底物进行快速紫外光裂解结合低温时间分辨电子显微镜（cryo-TREM）的方法，弥补了这一认识空白。我们阐明了膜结合型糖基转移酶 GtrB 的催化机制，该酶将葡萄糖从 UDP-葡萄糖转移至脂质载体十一烯醇磷酸。我们可视化了 GtrB（其活性位点距膜约 15 Å）在催化循环中如何转换，以使各底物靠近以促进催化反应。从单个数据集中，我们解析出不同的构象状态：初始底物结合态、催化预备中间态和产物结合态。通过分子动力学模拟与生化分析，我们发现活性位点内存在协调运动，驱动催化过程的进行。这些发现为理解糖基转移酶的分子作用机制提供了框架，并展示了一种广泛适用于捕获类原生环境中动态酶状态的策略。

### 第二部分 AI 大师评价

本研究旨在解析膜结合糖基转移酶 GtrB 在催化过程中的动态构象变化，利用化学封闭底物的快速光裂解及低温时间分辨电镜技术，创新性地捕获了不同催化中间态。研究通过结合分子动力学与生化分析揭示了活性位点的协调运动，为糖基转移酶的催化机制提供了分子层面的理解。该工作不仅拓展了结构生物学对酶动态过程的认识，也为在接近天然条件下研究动态酶状态提供了重要方法学启示。

---

## 5. 用于遗传互作文库筛选的下一代双导向 CRISPR 系统

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353404)
**期刊：** Nature communications
**PMID：** 41353404
**DOI：** 10.1038/s41467-025-67256-9

### 第一部分 原文与翻译

**英文原标题：** A next-generation dual guide CRISPR system for genetic interaction library screening.

> **英文摘要：**
> Pairwise perturbation of gene function using the CRISPR/Cas9 system has potential in screening for genetic interactions and synthetic lethal gene pairs to identify combination therapies for cancer. However, existing dual guide expression systems are cumbersome to clone, often result in a large proportion of undesired guide pairs and have an imbalance of guide expression from the two positions. Here, we demonstrate a next-generation system for dual guide delivery based around a tRNA spacer that allows a single-step cloning strategy, as little as 2% of undesired guide pairs, and highly balanced expression of the two guides. This system allows efficient library-scale screening for hundreds of thousands of genetic interactions using the well-understood Streptococcus pyogenes Cas9 (SpCas9) system. We use this to screen a 100,136 guide pair library in colorectal cancer cells and successfully identify synthetic lethal genetic interactions between paralogs or other known interacting genes, establishing our method for performing efficient large-scale genetic interaction screens. This system is versatile and could be used with most guide RNA vector systems, and for other uses of paired guide delivery, such as improving single gene knockout efficiency or improving guide detection in single cell or optical CRISPR screens.

> **中文摘要：**
> 利用 CRISPR/Cas9 系统对基因功能进行成对干扰，在筛选遗传互作和合成致死基因对、以识别癌症联合治疗靶点方面具有潜力。然而，现有的双导向表达系统在克隆过程中十分繁琐，常常产生大量非期望的导向序列配对，并且两个位置的导向 RNA 表达水平存在不平衡的问题。在此，我们展示了一种基于 tRNA 间隔子的下一代双导向递送系统，可实现单步克隆策略，非期望导向配对比例低至 2%，并实现两条导向 RNA 的高平衡表达。该系统利用成熟的化脓性链球菌 Cas9（SpCas9）体系，实现对数十万遗传互作用的高效文库级筛选。我们在结直肠癌细胞中对包含 100,136 对导向序列的文库进行了筛查，成功识别了同源基因或其他已知互作基因间的合成致死遗传互作，从而确立了我们进行大规模高效遗传互作筛选的方法。该系统具有很强的通用性，可适用于大多数导向 RNA 載体系统，并可用于其他成对导向递送的用途，例如提高单基因敲除效率或改善单细胞或光学 CRISPR 筛选中的导向检测。

### 第二部分 AI 大师评价

该研究旨在开发一种更高效、简化且表达平衡的双导向 CRISPR 系统，以应对现有系统在克隆复杂性和导向失衡上的局限。作者利用基于 tRNA 间隔子的设计，实现了单步克隆和低误配率，并在 SpCas9 框架下实现了大规模遗传互作文库筛选。该方法成功揭示了结直肠癌细胞中同源或互作基因的合成致死关系，展示了其在遗传互作图谱绘制和癌症治疗策略发现中的潜力。创新之处在于双导向构建流程的极大简化与高效率表达，但后续仍需验证其在其他细胞类型和 CRISPR 系统中的广泛适用性。

---

## 6. 自噬依赖性分泌的ENO1介导胶质母细胞瘤的化疗耐药性及肿瘤微环境重塑

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353343)
**期刊：** Cell death & disease
**PMID：** 41353343
**DOI：** 10.1038/s41419-025-08313-5

### 第一部分 原文与翻译

**英文原标题：** Autophagy-dependent secretion of ENO1 mediates chemoresistance of glioblastoma and tumor microenvironment remodeling.

> **英文摘要：**
> Acquired therapeutic resistance in glioblastoma multiforme (GBM) constitutes a major determinant of its refractory and tumor recurrence. Both tumor-intrinsic epigenetic regulation and tumor microenvironment (TME) remodeling are now understood to play pivotal roles in this resistance; however, the synergistic mechanisms and key molecular mediators underlying this interplay remain poorly defined. In this study, we demonstrated that temozolomide (TMZ) could activate the autophagy-dependent secretory pathway to promote extracellular secretion of Alpha-enolase (ENO1). Extracellular soluble ENO1 robustly enhanced GBM cell proliferation, migration, and invasion in vitro. Clinically, serum ENO1 levels were markedly elevated in GBM patients and strongly correlated with TMZ therapeutic response, suggesting its potential as a diagnostic biomarker for predicting TMZ efficacy. Mechanistically, secreted ENO1 could bind to the Toll-like receptor 4 (TLR4) receptor on GBM cells, enhancing the PI3K/Akt pathway to promote cell invasion and proliferation. Meanwhile, ENO1/TLR4 axis activated the downstream ERK/SPHK1 signaling cascade, inducing phosphorylation and membrane translocation of SPHK1 at Ser225, thereby promoting the biosynthesis of sphingosine-1-phosphate (S1P), a critical sphingolipid metabolite. Notably, extracellular ENO1 and its downstream metabolite S1P synergistically polarized tumor-associated macrophages (TAMs) toward an M2-like phenotype, fostering an immunosuppressive tumor microenvironment (TME) and conferring chemoresistance. Importantly, in vivo studies confirmed that combined therapy with the SPHK1 inhibitor PF-543, the TLR4 antagonist TAK-242, and TMZ synergistically suppressed tumor growth and significantly enhanced the efficacy of TMZ. Collectively, these findings reveal that ENO1 mediates intercellular crosstalk between GBM cells and M2-TAMs via autophagy-dependent secretion, thereby driving TMZ chemoresistance and functioning as an oncogene in GBM. Targeting the ENO1/TLR4 signaling axis reshapes the immune microenvironment and enhances the efficacy of TMZ, offering a promising therapeutic strategy and potential combinatorial targets for precision therapy in GBM.

> **中文摘要：**
> 获得性治疗耐药性是多形性胶质母细胞瘤（GBM）顽固性和肿瘤复发的主要决定因素。肿瘤内在的表观遗传调控及肿瘤微环境（TME）重塑已被认为在这种耐药性中起关键作用；然而，二者之间相互作用的协同机制及其主要分子介质仍未明晰。在本研究中，我们发现替莫唑胺（TMZ）可激活自噬依赖的分泌途径，促进α-烯醇化酶（ENO1）的胞外分泌。可溶性胞外ENO1在体外显著增强了GBM细胞的增殖、迁移和侵袭能力。临床上，GBM患者的血清ENO1水平显著升高，并与TMZ治疗反应密切相关，提示其作为预测TMZ疗效的诊断性生物标志物的潜力。在机制上，分泌的ENO1可与GBM细胞表面的Toll样受体4（TLR4）结合，增强PI3K/Akt信号通路，从而促进细胞的侵袭与增殖。同时，ENO1/TLR4轴激活下游的ERK/SPHK1信号级联，诱导SPHK1在Ser225位点的磷酸化及膜转位，从而促进鞘氨醇-1-磷酸（S1P）这一关键鞘脂代谢物的生物合成。值得注意的是，胞外ENO1及其下游代谢产物S1P协同促使肿瘤相关巨噬细胞（TAMs）向M2型表型极化，推动免疫抑制型TME形成并赋予肿瘤化疗耐药性。重要的是，体内研究证实，SPHK1抑制剂PF-543、TLR4拮抗剂TAK-242与TMZ的联合治疗可协同抑制肿瘤生长并显著增强TMZ疗效。总体而言，这些发现表明，ENO1通过自噬依赖性分泌介导GBM细胞与M2型TAMs之间的细胞间互作，从而驱动TMZ化疗耐药，并作为GBM中的致癌基因发挥作用。靶向ENO1/TLR4信号轴可重塑免疫微环境并提高TMZ疗效，为GBM的精准治疗提供了新的治疗策略与潜在联合靶点。

### 第二部分 AI 大师评价

本文揭示了自噬依赖的ENO1分泌在胶质母细胞瘤化疗耐药性和肿瘤微环境重塑中的关键作用。研究通过体内外实验系统阐明ENO1通过TLR4受体激活PI3K/Akt及ERK/SPHK1信号通路，促进S1P生成，从而驱动肿瘤细胞侵袭与免疫抑制性TME形成。临床相关性分析加强了其作为潜在血清生物标志物的意义，同时联合靶向ENO1/TLR4及SPHK1通路显著提高TMZ疗效。研究在机制层面具有创新性，但后续仍需验证其在更大人群样本及临床转化中的可行性。

---

## 7. 基于抗CD38的四联方案在不适合移植的新诊断多发性骨髓瘤患者中的生存影响：网络荟萃分析与重建个体患者数据荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353340)
**期刊：** Blood cancer journal
**PMID：** 41353340
**DOI：** 10.1038/s41408-025-01413-7

### 第一部分 原文与翻译

**英文原标题：** Survival impact of anti-CD38-based quadruplet regimens in transplant-ineligible newly diagnosed multiple myeloma: a network meta-analysis and reconstructed individual patient data meta-analysis.

> **英文摘要：**
> Frontline therapy for transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) has advanced with anti-CD38 monoclonal antibody (mAb)-based regimens. Although quadruplet combinations incorporating daratumumab and isatuximab have demonstrated improved response rates and progression-free survival (PFS), comparative overall survival (OS) data remain limited. We performed a systematic review, network meta-analysis (NMA), and reconstructed individual patient data meta-analysis comparing survival outcomes of quadruplet versus triplet regimens in TI-NDMM. This study adhered to Cochrane and PRISMA guidelines and was registered prospectively (PROSPERO CRD420251033401). A comprehensive literature search through April 2025 identified randomized clinical trials (RCT) evaluating quadruplet and triplet regimens involving daratumumab, isatuximab, bortezomib, lenalidomide, and dexamethasone in any combination, compared to their backbone regimens, reporting OS and PFS. Four RCT (n = 2,038) were included. At 60 months, estimated PFS rates were: D-VRd (66.4%), I-VRd (63.2%), D-Rd (51.9%), and VRd (42.6%). Both D-VRd and I-VRd significantly improved PFS compared with D-Rd (HR 0.65; 95% CI 0.48-0.87; and HR 0.68; 95% CI 0.52-0.89) and VRd (HR 0.51; 95% CI 0.39-0.67; and HR 0.53; 95% CI 0.41-0.67). D-Rd also showed superior PFS over VRd (HR 0.77, 95% CI 0.64-0.93; P = 0.007). At 60 months, OS rates were: D-VRd (72.8%), I-VRd (72.2%), D-Rd (67.1%), and VRd (67.0%). Pooled analyses demonstrated that quadruplets significantly improved both PFS (64.7% vs. 46.3%; HR 0.57, 95% CI 0.47-0.69; P < 0.0001) and OS (72.5% vs. 67.1%; HR 0.78, 95% CI 0.63-0.96; P = 0.02) compared to triplet regimens. The OS benefit of quadruplets was consistent in comparisons against both D-Rd (HR 0.77; 95% CI: 0.60-0.98; P = 0.04) and VRd (HR 0.77; 95% CI: 0.62-0.97; P = 0.02). In the NMA, quadruplet regimens ranked highest for complete response, PFS, and OS. This meta-analysis supports anti-CD38 mAb-based quadruplet regimens as superior frontline therapy in TI-NDMM, significantly improving overall survival.

> **中文摘要：**
> 针对不适合移植的新诊断多发性骨髓瘤（TI-NDMM）的初始治疗，基于抗CD38单克隆抗体（mAb）的方案取得了进展。尽管包含达雷妥尤单抗和伊沙妥昔单抗的四联方案已显示出更高的应答率和更长的无进展生存期（PFS），但对比的总生存期（OS）数据仍然有限。本研究进行了系统综述、网络荟萃分析（NMA）以及重建个体患者数据的荟萃分析，以比较TI-NDMM中四联方案与三联方案的生存结局。本研究遵循Cochrane与PRISMA指南，并进行了前瞻性注册（PROSPERO CRD420251033401）。截至2025年4月的系统检索纳入了评估包含达雷妥尤单抗、伊沙妥昔单抗、硼替佐米、来那度胺及地塞米松等任意组合的四联或三联方案的随机对照试验（RCT），并报告OS与PFS结果。共纳入4项RCT（n=2,038）。在60个月时，估算的PFS分别为：D-VRd（66.4%）、I-VRd（63.2%）、D-Rd（51.9%）和VRd（42.6%）。与D-Rd相比，D-VRd和I-VRd均显著改善PFS（HR分别为0.65；95% CI 0.48–0.87 和 0.68；95% CI 0.52–0.89），与VRd相比亦有显著优势（HR分别为0.51；95% CI 0.39–0.67 和 0.53；95% CI 0.41–0.67）。此外，D-Rd较VRd也显示更优的PFS（HR 0.77；95% CI 0.64–0.93；P=0.007）。在60个月时，OS分别为：D-VRd（72.8%）、I-VRd（72.2%）、D-Rd（67.1%）和VRd（67.0%）。汇总分析显示，与三联方案相比，四联方案显著改善PFS（64.7% 对 46.3%；HR 0.57；95% CI 0.47–0.69；P<0.0001）和OS（72.5% 对 67.1%；HR 0.78；95% CI 0.63–0.96；P=0.02）。四联方案相较于D-Rd（HR 0.77；95% CI 0.60–0.98；P=0.04）及VRd（HR 0.77；95% CI 0.62–0.97；P=0.02）的OS获益均一致。在网络荟萃分析中，四联方案在完全缓解率、PFS及OS方面均居首位。本荟萃分析支持基于抗CD38 mAb的四联方案作为TI-NDMM的一线首选治疗，可显著改善总体生存。

### 第二部分 AI 大师评价

本研究系统评价了基于抗CD38单抗的四联方案在不适合移植的新诊断多发性骨髓瘤患者中的生存获益。通过网络荟萃分析和重建个体患者数据分析，结果显示四联方案相比三联方案在无进展生存期和总生存期方面均有显著改善。该研究严格遵循Cochrane与PRISMA标准，证实达雷妥尤单抗或伊沙妥昔单抗联合方案的优越性。其创新之处在于整合不同RCT数据并评估真实世界的生存比较，然而受限于样本规模及数据重建的间接性，仍需进一步验证其长期安全性与疗效一致性。

---

## 8. 肌动蛋白失调诱导神经内分泌可塑性与免疫逃逸：小细胞肺癌的潜在脆弱性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353272)
**期刊：** Nature communications
**PMID：** 41353272
**DOI：** 10.1038/s41467-025-67078-9

### 第一部分 原文与翻译

**英文原标题：** Actin dysregulation induces neuroendocrine plasticity and immune evasion: a vulnerability of small cell lung cancer.

> **英文摘要：**
> Small cell lung cancer (SCLC) is an aggressive malignancy with limited therapeutic options. Capping protein inhibiting regulator of actin dynamics (CRACD) that promotes actin polymerization, is frequently inactivated in SCLC. However, the role of CRACD loss in SCLC is unknown. Here we show that CRACD depletion drives neuroendocrine (NE) cell plasticity and immune evasion in SCLC. Mechanistically, CRACD inactivation disrupts actin organization, leading to suppression of Yap1-NOTCH signaling and subsequent NE gene upregulation. Simultaneously, CRACD loss drives EZH2-mediated histone methylation via nuclear actin disruption, leading to repression of MHC-I genes and depletion of CD8⁺ T cells. Consequently, CRACD-downregulated tumors exhibit increased cellular heterogeneity and escape from immune surveillance. Conversely, pharmacological inhibition of EZH2 restores MHC-I expression, reactivates antitumor immunity, and suppresses tumor growth. These findings identify CRACD as a tumor suppressor that constrains cell plasticity and immune evasion, highlighting the CRACD-EZH2-MHC-I axis as a potential therapeutic vulnerability in SCLC.

> **中文摘要：**
> 小细胞肺癌（SCLC）是一种侵袭性强且治疗选择有限的恶性肿瘤。肌动蛋白动力学封端蛋白抑制调控因子（CRACD）可促进肌动蛋白聚合，但在SCLC中常发生失活。然而，CRACD丧失在SCLC中的作用尚不清楚。本研究显示，CRACD耗竭可在SCLC中驱动神经内分泌（NE）细胞可塑性和免疫逃逸。从机制上看，CRACD失活会破坏肌动蛋白结构，导致Yap1-NOTCH信号通路受抑制，并随之诱导NE相关基因上调。同时，CRACD缺失通过破坏细胞核内肌动蛋白的完整性，促进EZH2介导的组蛋白甲基化，从而抑制MHC-I基因表达并导致CD8⁺ T细胞减少。结果表明，CRACD下调的肿瘤表现出更高的细胞异质性，并能逃避免疫监视。相反，药理性抑制EZH2可恢复MHC-I的表达，重新激活抗肿瘤免疫，并抑制肿瘤生长。这些发现确定CRACD是一种抑癌基因，可限制细胞可塑性与免疫逃逸，并凸显CRACD–EZH2–MHC-I轴作为SCLC潜在治疗靶点的意义。

### 第二部分 AI 大师评价

该研究聚焦于小细胞肺癌中CRACD基因的功能缺失，揭示其通过影响肌动蛋白重组和相关信号通路，驱动神经内分泌表型转化及免疫逃逸。研究采用机制性实验验证了CRACD失活在EZH2介导的表观调控和MHC-I下调中的作用，并通过药理抑制实验展示了潜在的治疗可行性。该发现为理解SCLC的细胞异质性及免疫抑制机制提供了新视角，同时为靶向CRACD–EZH2–MHC-I轴的治疗策略奠定了基础，但仍需在临床水平验证其转化应用价值。

---

## 9. CSDE1消减通过增强B细胞浸润抑制非小细胞肺癌的肿瘤进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353256)
**期刊：** Cell death & disease
**PMID：** 41353256
**DOI：** 10.1038/s41419-025-08282-9

### 第一部分 原文与翻译

**英文原标题：** CSDE1 depletion inhibits tumor progression through enhancing B-cell infiltration in NSCLC.

> **英文摘要：**
> Although most immunotherapy research focuses on T cells, increasing evidence highlights the significant role of tumor-infiltrating B lymphocytes (TIL-Bs) in cancer therapy. CSDE1 has been implicated in various cancers and immune responses. This study investigates the role of CSDE1 in lung cancer progression and its impact on the tumor immune microenvironment. We found that CSDE1 promotes lung cancer progression in vivo but not in vitro. Using the tumor-bearing mice model with Csde1 knockout, we demonstrated that Csde1 deletion significantly inhibited tumor growth. Single-cell RNA sequencing revealed that Csde1 knockout reshaped the tumor immune microenvironment, particularly by significantly increasing TIL-B levels, a finding confirmed by flow cytometry and immunofluorescence. Moreover, Csde1 knockout enhanced B-cell-mediated humoral immunity. Notably, depleting B cells in Csde1 knockout mice reversed the inhibitory effect of Csde1 deletion on tumor progression, underscoring the critical role of B cells in this process. These findings suggest that CSDE1 facilitates tumor progression by modulating TIL-Bs and the broader immune microenvironment. This study provides a new potential target and valuable insights into tumor immunotherapy, emphasizing the importance of B cells in cancer treatment strategies.

> **中文摘要：**
> 尽管大多数免疫治疗研究集中于T细胞，但越来越多的证据强调了肿瘤浸润性B淋巴细胞（TIL-Bs）在癌症治疗中的重要作用。CSDE1被认为与多种癌症和免疫反应相关。本研究探讨了CSDE1在肺癌进展中的作用及其对肿瘤免疫微环境的影响。我们发现，CSDE1在体内促进肺癌进展，但在体外则无此作用。利用携瘤小鼠的Csde1敲除模型，我们证明了Csde1缺失可显著抑制肿瘤生长。单细胞RNA测序结果显示，Csde1敲除重塑了肿瘤免疫微环境，尤其表现为显著增加TIL-B水平，这一发现通过流式细胞术和免疫荧光得到了验证。此外，Csde1敲除增强了B细胞介导的体液免疫反应。值得注意的是，在Csde1敲除小鼠中耗竭B细胞可逆转Csde1缺失对肿瘤进展的抑制作用，突出了B细胞在该过程中的关键作用。这些发现表明，CSDE1通过调控TIL-Bs及更广泛的免疫微环境促进肿瘤进展。本研究为肿瘤免疫治疗提供了新的潜在靶点和重要见解，强调了B细胞在癌症治疗策略中的重要性。

### 第二部分 AI 大师评价

该研究聚焦于CSDE1在非小细胞肺癌（NSCLC）中的免疫调控作用，揭示其通过影响B细胞浸润促进肿瘤进展。作者结合体内小鼠模型、单细胞转录组、流式细胞术及免疫荧光等手段，系统阐明了Csde1敲除对肿瘤免疫微环境的重塑效应。研究创新性地凸显了B细胞在肿瘤免疫中的核心功能，为免疫治疗靶点开发提供了新思路。其局限在于对CSDE1具体分子机制及其与其他免疫细胞互作的探讨仍需进一步深入。

---

## 10. AQB 通过双重 DNA 修复调控提高子宫内膜癌对卡铂的敏感性：抑制 p21-E2F1-RAD51 与 ATF3-HDAC1-BRCA1 信号通路。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353219)
**期刊：** Cell death & disease
**PMID：** 41353219
**DOI：** 10.1038/s41419-025-08287-4

### 第一部分 原文与翻译

**英文原标题：** AQB improves carboplatin sensitivity in endometrial cancer through dual DNA repair modulation: suppression of the p21-E2F1-RAD51 and ATF3-HDAC1-BRCA1 signaling.

> **英文摘要：**
> Endometrial cancer (EC) is an increasingly common malignancy among women, and associated mortality rates continue to rise. Preferred treatment options for advanced or recurrent EC patients include a combination of carboplatin and paclitaxel, with modest clinical outcomes. Chemoresistance and drug toxicity are important factors that significantly affect the clinical efficacy of carboplatin. Therefore, there is an urgent need for therapeutic strategies that enhance carboplatin sensitivity, reduce its dose while maintaining efficacy, and ensure treatment safety. This study identified the novel small-molecule inhibitor AC1Q3QWB (AQB) as a potent enhancer of carboplatin efficacy. AQB disrupts the binding of HOTAIR to EZH2 and upregulates a series of tumor suppressor genes, such as CDKN1A, ATF3, and BBC3, thereby epigenetically suppressing the homologous recombination repair (HRR) pathway in EC, causing cell cycle arrest and inducing apoptosis. AQB inhibits carboplatin-induced RAD51 expression via the p21-E2F1 axis. Additionally, AQB epigenetically silences BRCA1 via ATF3-HDAC1 interactions at the BRCA1 promoter. In vivo studies using subcutaneous xenografts and a stage IV EC patient-derived xenograft (PDX) model demonstrated that AQB enhanced carboplatin's antitumor effects, reduced the required carboplatin dose, and alleviated associated toxicity. The combination of AQB with standard chemotherapy holds promise for improving outcomes in patients with advanced or recurrent EC.The schematic diagram illustrates the mechanism by which AQB enhances the sensitivity of EC cells to CBPt.

> **中文摘要：**
> 子宫内膜癌（EC）是女性中日益常见的恶性肿瘤，其相关死亡率持续上升。晚期或复发性 EC 患者的首选治疗方案通常是卡铂与紫杉醇的联合应用，但临床疗效有限。化疗耐药性和药物毒性是显著影响卡铂临床疗效的重要因素。因此，迫切需要能够增强卡铂敏感性、在保证疗效的同时降低剂量并确保治疗安全性的策略。本研究鉴定出一种新型小分子抑制剂 AC1Q3QWB（AQB），其可显著增强卡铂的疗效。AQB 通过破坏 HOTAIR 与 EZH2 的结合，上调一系列抑癌基因（如 CDKN1A、ATF3 和 BBC3），从而在表观遗传水平上抑制 EC 中的同源重组修复（HRR）通路，引起细胞周期阻滞并诱导凋亡。AQB 通过 p21-E2F1 轴抑制卡铂诱导的 RAD51 表达。此外，AQB 在 BRCA1 启动子区域通过 ATF3-HDAC1 相互作用在表观遗传水平上沉默 BRCA1。采用皮下异种移植和来源于一例 IV 期 EC 患者的异种移植（PDX）模型的体内研究表明，AQB 可增强卡铂的抗肿瘤效应，减少所需卡铂剂量，并减轻相关毒性。AQB 与标准化疗的联合应用有望改善晚期或复发性 EC 患者的治疗结局。示意图阐释了 AQB 增强 EC 细胞对卡铂敏感性的机制。

### 第二部分 AI 大师评价

该研究揭示了一种通过表观遗传调控双重 DNA 修复通路从而提升卡铂敏感性的策略。研究者发现小分子抑制剂 AQB 可同时抑制 p21-E2F1-RAD51 与 ATF3-HDAC1-BRCA1 信号轴，降低 DNA 同源重组修复活性，使子宫内膜癌细胞更易被卡铂杀伤。体内外实验均显示 AQB 能增强卡铂疗效并减少毒性，具有潜在的临床转化价值。其创新在于通过长链非编码 RNA 与表观调控网络靶向 DNA 修复途径，但后续仍需验证其药代学特性与安全性。

---

## 11. β-连环蛋白的凝聚促进钙黏蛋白/连环蛋白复合物的聚集及新生细胞-细胞连接的形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353217)
**期刊：** Nature communications
**PMID：** 41353217
**DOI：** 10.1038/s41467-025-66984-2

### 第一部分 原文与翻译

**英文原标题：** β-catenin condensation facilitates clustering of the cadherin/catenin complex and formation of nascent cell-cell junctions.

> **英文摘要：**
> Cadherin-based junctions establish dynamically regulated adhesion between cells to coordinate tissue integrity and morphogenetic movements. Adhesion strength can be modulated by the organization of individual cadherin complexes into lateral clusters. Here, we identify a clustering mechanism of the cadherin complex established by its core component β-catenin. We show that the disordered termini of β-catenin drive the formation of condensates that incorporate other components of the cadherin complex in vitro. Using β-catenin mutants with hampered condensation, we demonstrate that β-catenin condensation nucleates the formation of submicron cadherin/catenin clusters that further develop into stable sites of adhesion. Furthermore, we show that β-catenin-dependent clustering ensures the efficient formation of de novo cell-cell adhesions. Our data thus indicate a role for β-catenin condensates in the supramolecular organization of the cadherin complex, and reveal that the function of β-catenin in the cadherin complex extends beyond connecting cadherin to α-catenin and the actin cytoskeleton.

> **中文摘要：**
> 基于钙黏蛋白的连接在细胞之间建立动态调控的黏附，以协调组织完整性和形态发生运动。黏附强度可以通过单个钙黏蛋白复合物沿侧向聚集成簇的组织方式进行调节。在本研究中，我们鉴定出一种由其核心组分β-连环蛋白介导的钙黏蛋白复合物聚集机制。我们显示，β-连环蛋白无序的末端驱动体外包含其他钙黏蛋白复合物组分的凝聚体形成。利用抑制其凝聚能力的β-连环蛋白突变体，我们证实β-连环蛋白的凝聚可诱导形成亚微米级钙黏蛋白/连环蛋白簇，这些簇进一步发展为稳定的黏附位点。此外，我们表明，依赖β-连环蛋白的聚集确保了新生细胞间黏附的高效形成。因此，我们的数据表明β-连环蛋白凝聚体在钙黏蛋白复合物的超分子组织中发挥作用，并揭示其功能不仅限于连接钙黏蛋白、α-连环蛋白及肌动蛋白细胞骨架。

### 第二部分 AI 大师评价

本研究聚焦于β-连环蛋白在钙黏蛋白复合物聚集和细胞间黏附形成中的关键作用。研究者通过体外实验与突变体分析，揭示β-连环蛋白末端无序结构促进复合物凝聚与亚微米级聚集的机制。结果表明，该过程对新生细胞连接的形成至关重要，拓展了β-连环蛋白在细胞连接中的功能理解。该研究为揭示细胞黏附的分子组织提供了新视角，但其体内调控机制及与信号通路的关系仍有待进一步验证。

---

## 12. OPRK1 促进 SLC9A3R1 向神经内分泌型前列腺癌的进展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353213)
**期刊：** Cell death & disease
**PMID：** 41353213
**DOI：** 10.1038/s41419-025-08279-4

### 第一部分 原文与翻译

**英文原标题：** OPRK1 drives SLC9A3R1 progression to neuroendocrine prostate cancer.

> **英文摘要：**
> Neuroendocrine differentiation (NED) plays a critical role in endocrine therapy resistance and dismal outcomes among prostate cancer (PCa) patients. The emergence of treatment-induced neuroendocrine prostate cancers (t-NEPCs) with the utilization of second-generation androgen receptor (AR) pathway inhibitors (ARPIs) poses a significant challenge, as the molecular underpinnings remain elusive. Here, our investigation unveils a close correlation between heightened levels of opioid receptor membrane protein OPRK1 and treatment-induced NED (t-NED), alongside an adverse prognosis in PCa cohorts. Our findings illuminate that AR represses OPRK1 transcription by binding to its promoter, a regulation amenable to reversal via ARPI administration. Further exploration reveals that OPRK1 stimulation triggers autophagic degradation of REST upon up-regulation and interaction with SLC9A3R1, thereby instigating NED. In essence, OPRK1 experiences negative control by AR and emerges as a pivotal instigator of t-NED. Combining JTC-801 with CQ successfully impedes NEPC progression by impacting the OPRK1/SLC9A3R1/autophagy/REST axis. Our study accentuates OPRK1 as a novel therapeutic target for PCa management and furnishes profound insights into the pathogenesis of t-NEPC.

> **中文摘要：**
> 神经内分泌分化（NED）在前列腺癌（PCa）患者的内分泌治疗耐药性和不良预后中起关键作用。随着第二代雄激素受体（AR）通路抑制剂（ARPI）的应用，治疗诱导的神经内分泌型前列腺癌（t-NEPC）的出现成为重大挑战，因为其分子机制仍不清楚。本研究揭示，阿片受体膜蛋白OPRK1表达水平升高与治疗诱导的NED（t-NED）密切相关，并伴随PCa患者的不良预后。研究结果显示，AR通过与OPRK1启动子结合抑制其转录，而这一调控可被ARPI治疗逆转。进一步研究表明，OPRK1的激活在上调并与SLC9A3R1相互作用后，会引发REST的自噬降解，从而推动NED的发生。本质上，OPRK1受到AR的负向调控，并成为t-NED的重要驱动因子。联合使用JTC-801与CQ可通过影响OPRK1/SLC9A3R1/自噬/REST轴有效阻止NEPC的进展。本研究强调了OPRK1作为前列腺癌管理的新型治疗靶点的重要性，并为t-NEPC的发病机制提供了重要见解。

### 第二部分 AI 大师评价

该研究旨在阐明治疗诱导型神经内分泌前列腺癌（t-NEPC）的分子机制，重点探索阿片受体OPRK1的作用。作者发现AR通过转录水平抑制OPRK1，而ARPI治疗解除这一抑制，从而促进OPRK1上调并诱导NED形成。机制上，OPRK1通过与SLC9A3R1相互作用引发REST的自噬降解，推动神经内分泌分化。研究创新性地揭示了OPRK1/SLC9A3R1/自噬/REST通路在t-NEPC中的关键作用，并提出JTC-801与CQ组合为潜在治疗策略，然而其在临床转化中的安全性与效果仍需进一步验证。

---

## 13. 跨人群前列腺癌风险的蛋白质组范围关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353205)
**期刊：** Nature communications
**PMID：** 41353205
**DOI：** 10.1038/s41467-025-66250-5

### 第一部分 原文与翻译

**英文原标题：** Proteome-wide association study of prostate cancer risk across populations.

> **英文摘要：**
> There is insufficient understanding of the molecular basis of prostate cancer (PCa) across different populations. We perform a large-scale proteome-wide association study (PWAS) to identify proteins with genetically regulated expression in plasma to be associated with PCa risk across populations. We develop genetic prediction models for expression of 1578, 1993, 1218, and 1390 proteins for African (n = 450), European (n = 758), Asian (n = 289), and Hispanic/Latino (n = 474) males, respectively, and evaluate associations of genetically regulated protein expression with PCa risk in 19,391 PCa cases and 61,608 controls of African population, 122,188 cases and 604,640 controls of European population, 10,809 cases and 95,790 controls of Asian population, and 3931 cases and 26,405 controls of Hispanic/Latino population. We identify three, four, 15, and 73 PCa-associated proteins in African, Hispanic/Latino, Asian, and European populations, respectively, and 83 in trans-population meta-analysis. There are both pan-population and population-specific associations. Our findings provide valuable insights into etiology of PCa.

> **中文摘要：**
> 目前对不同人群中前列腺癌（PCa）的分子基础缺乏充分的理解。我们开展了一项大规模的蛋白质组范围关联研究（PWAS），旨在识别那些在血浆中基因调控表达的蛋白质，这些蛋白质可能与不同人群的PCa风险相关。我们分别为非洲裔（n = 450）、欧洲裔（n = 758）、亚洲裔（n = 289）和西班牙裔/拉丁裔（n = 474）男性建立了蛋白质表达的遗传预测模型，预测的蛋白数量分别为1578、1993、1218和1390个，并评估这些基因调控的蛋白表达与PCa风险之间的关联。在非洲裔人群（19,391例病例和61,608名对照）、欧洲裔人群（122,188例病例和604,640名对照）、亚洲裔人群（10,809例病例和95,790名对照）以及西班牙裔/拉丁裔人群（3931例病例和26,405名对照）中进行分析。结果分别在非洲裔、西班牙裔/拉丁裔、亚洲裔和欧洲裔人群中鉴定出3个、4个、15个和73个与PCa相关的蛋白质，并在跨人群的Meta分析中鉴定出83个相关蛋白。研究发现既存在跨人群共有的关联，也存在特定人群特异性的关联。我们的研究结果为理解前列腺癌的病因学提供了有价值的见解。

### 第二部分 AI 大师评价

本研究通过在不同人群中开展大规模蛋白质组范围关联分析，建立遗传调控蛋白表达的预测模型，系统识别出与前列腺癌风险相关的蛋白。研究整合了非洲、欧洲、亚洲及西班牙裔/拉丁裔多种族群数据，揭示了既存在跨人群共有的风险蛋白，也存在人群特异的分子关联。这种多族群PWAS设计显著拓宽了对前列腺癌分子机制的理解，为精准防控提供了潜在线索。研究的创新在于跨族群整合分析，但不同样本量与群体遗传结构差异可能影响结果的可推广性。

---

## 14. JAK/STAT-Pdk1-S6K 轴通过绕过系统性生长限制促进再生

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41353199)
**期刊：** Nature communications
**PMID：** 41353199
**DOI：** 10.1038/s41467-025-66995-z

### 第一部分 原文与翻译

**英文原标题：** A JAK/STAT-Pdk1-S6K axis bypasses systemic growth restrictions to promote regeneration.

> **英文摘要：**
> Inflammation triggers systemic growth restrictions, a process well characterised in tumour cachexia. Whether inflammatory tissue damage also induces growth restrictions, and how regenerating tissue overcome them, is less explored. Using a tissue damage model in Drosophila, we identify metabolic and signaling adaptations that both induce and bypass systemic growth restrictions. Expression of eiger, the Drosophila TNF-α homolog, in imaginal discs causes systemic insulin restriction and insulin resistance, reducing protein translation and proliferation in peripheral tissues. Regenerating cells overcome this by upregulating Pdk1, which is necessary and sufficient to promote protein translation via an Insulin/Akt-independent mechanism. JAK/STAT acts upstream to elevate Pdk1, defining a JAK/STAT-Pdk1-S6K axis essential for regenerative proliferation. Regenerating cells also upregulate amino acid transporters and rely on mTORC1. Similar signatures in Ras, scrib tumors indicate that tumors co-opt these pathways to sustain growth under insulin restriction. This physiological program thus integrates systemic nutrient mobilization and local metabolic reprogramming, with implications for tissue repair but also pathologies, such as chronic wounds and cancer.

> **中文摘要：**
> 炎症会触发系统性生长限制，这一过程在肿瘤恶病质中已被充分表征。然而，炎症性组织损伤是否同样会诱导生长限制，以及再生组织如何克服这种限制，尚未得到充分研究。通过使用果蝇的组织损伤模型，我们识别出既能诱导又能绕过系统性生长限制的代谢与信号通路适应机制。在想象盘中表达果蝇的 TNF-α 同源物 eiger，会导致系统性胰岛素限制和胰岛素抵抗，从而降低外周组织中的蛋白质翻译和细胞增殖。再生细胞通过上调 Pdk1 来克服这一障碍，Pdk1 的上调对于促进蛋白质翻译是必需且充分的，并且通过一种独立于胰岛素/Akt 的机制实现。JAK/STAT 通路在上游作用以提升 Pdk1 的表达，进而定义了一个对再生性增殖至关重要的 JAK/STAT-Pdk1-S6K 轴。再生细胞还上调氨基酸转运体并依赖于 mTORC1 信号。Ras 和 scrib 突变肿瘤中出现的类似特征表明，肿瘤也会劫持这些通路以在胰岛素受限条件下维持生长。因此，这一生理程序整合了系统性营养动员与局部代谢重编程，对组织修复以及慢性创伤、癌症等病理状态具有重要启示。

### 第二部分 AI 大师评价

该研究利用果蝇组织损伤模型揭示了炎症引发的系统性生长限制及其被再生组织克服的机制。作者发现，JAK/STAT 通路通过上调 Pdk1 激活 S6K，从而独立于胰岛素/Akt 通路促进蛋白合成与细胞增殖，构建了一个新的再生信号轴。研究还表明再生细胞增强氨基酸摄取并依赖 mTORC1，而肿瘤可能利用同样的策略以维持生长。该工作将系统代谢调控与组织再生机制相连接，深化了对炎症后再生和肿瘤生物学的理解，但其在哺乳动物模型中的普适性仍需进一步验证。

---

## 15. 发育本源决定儿童白血病的致癌潜能、谱系层级及治疗反应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41351880)
**期刊：** Cancer discovery
**PMID：** 41351880
**DOI：** 10.1158/2159-8290.CD-25-0556

### 第一部分 原文与翻译

**英文原标题：** Ontogeny Dictates Oncogenic Potential, Lineage Hierarchy, and Therapy Response in Pediatric Leukemia.

> **英文摘要：**
> UNLABELLED: Accumulating evidence links pediatric cancers to prenatal transformation events, yet the influence of the developmental stage on oncogenesis remains elusive. We investigated how hematopoietic stem cell developmental stages affect leukemic transformation, disease progression, and therapy response using a novel, humanized model of NUP98::NSD1-driven pediatric acute myeloid leukemia that is particularly aggressive with WT1 comutations. Fetal-derived hematopoietic stem cells readily transform into leukemia, and WT1 mutations further enhance stemness and alter lineage hierarchy. In contrast, stem cells from later developmental stages become progressively resistant to transformation. Single-cell analyses revealed that fetal-origin leukemia stem cells exhibit greater quiescence and reliance on oxidative phosphorylation than their postnatal counterparts. These differences drive distinct therapeutic responses despite identical oncogenic mutations. In patients, onco-fetal transcriptional programs correlate with worse outcomes. By targeting key vulnerabilities of fetal-origin leukemia cells, we identified combination therapies that significantly reduce aggressiveness, highlighting the critical role of ontogeny in pediatric cancer treatment.
> 
> SIGNIFICANCE: This study signifies the critical consequences of developmental timing in cancer initiation, revealing that identical driver mutations in fetal- versus postnatal-origin leukemias exhibit fundamentally distinct biology and treatment responses. Recognizing these developmental differences opens avenues for personalized therapeutic strategies, improving outcomes for pediatric patients with aggressive disease subtypes in leukemia.

> **中文摘要：**
> 未标注：累积的证据已将儿童癌症与产前转化事件联系起来，但发育阶段对肿瘤发生的影响仍不清楚。我们利用一种新型的人源化模型研究了造血干细胞发育阶段如何影响白血病的转化、疾病进展和治疗反应。该模型为由 NUP98::NSD1 驱动的儿童急性髓系白血病，在存在 WT1 共突变时表现出特别的侵袭性。胎源性造血干细胞易于转化为白血病，而 WT1 突变进一步增强其干性并改变谱系层级。相反，来自较晚发育阶段的干细胞对转化逐渐表现出抵抗性。单细胞分析显示，胎源性白血病干细胞相比出生后来源者展现出更强的静息性，并依赖于氧化磷酸化。这些差异导致即便存在相同的致癌突变，也产生不同的治疗反应。在患者中，肿瘤-胎源性转录程序与较差的预后密切相关。通过针对胎源性白血病细胞的关键脆弱环节，我们鉴定出能够显著降低侵袭性的联合治疗方案，强调了发育起源在儿童癌症治疗中的关键作用。
> 
> 重要性：本研究揭示了发育时序在癌症起始中的关键后果，表明相同的驱动突变在胎源性与出生后来源的白血病中呈现根本不同的生物学特征和治疗反应。认识到这些发育差异为个体化治疗策略开辟了新途径，有望改善侵袭性儿童白血病亚型患者的预后。

### 第二部分 AI 大师评价

该研究以儿童白血病为模型，系统揭示了造血干细胞发育阶段对致癌潜能、谱系层级及治疗反应的决定性影响。作者利用人源化的 NUP98::NSD1 驱动模型，发现胎源性干细胞更易恶变，且依赖不同的代谢通路，从而产生不同的药物应答。研究强调了相同致癌突变在不同发育阶段的多样生物学表现，提出了针对胎源性脆弱性的联合治疗思路。这一发现不仅拓宽了儿童肿瘤发生机制的认知，也为精准分型与个体化治疗提供了方向。

---

速递结束，祝您工作愉快！